Thought Leadership

Latest Report


Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020

Biopharma was not exempt from the initial shock of a global pandemic, but the worst projections have not happened and the initial beneficiaries have now emerged. After a near universal first quarter stumble, big and medium cap pharma companies finished the half in style, with stocks up $190bn since the end of 2019. The picture is even better for…

Report library


EvaluatePharma Orphan Drug Report 2019

$242bn forecasted orphan drug sales by 2024, one-fifth of the total worldwide pharmaceutical market The EvaluatePharma Orphan Drug Report 2019 arrives at the start of a…


Vantage 2019 Preview

2019 expected to be volatile year for pharma and biotech industries The Vantage 2019 Preview looks at the risks and opportunities for the year ahead. Report…